Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
PNMA family member 1 (PNMA1)
- Target
- PNMA1
- Molecular classification
- Other (neuron- and testis-specific protein; not a typical receptor, enzyme, or ion channel), Antigen (specifically associated with paraneoplastic antigens), Protein coding gene
01
Overview
PNMA family member 1 (PNMA1) is a protein predominantly expressed in neurons and testis, and also found in association with paraneoplastic neurological syndromes affecting the nervous system. The PNMA protein family is characterized by conserved sequence homology to retrotransposon gag proteins and a role in cell signaling and apoptosis, especially within the brain. PNMA1 is immunogenic in cancer patients exhibiting paraneoplastic syndromes, and antibodies against PNMA1 can be used for diagnostic purposes. While its broader physiological function remains incompletely understood, altered or aberrant expression of PNMA1 and related family proteins is implicated in cancer biology and various rare genetic disorders.
- Other names
- PNMA1Paraneoplastic antigen MA1Paraneoplastic Ma antigen 1Ma1 protein
02
Mechanism of action
For antibody-based agents: immune recognition of the antigen, leading to diagnostic utility. Not directly targeted by therapeutic small molecules; mechanism for would-be therapies might involve modulating immune response or interfering with antigen presentation.
03
Biological functions
Signal transductionApoptosis (reported involvement in cell death signaling)Neuronal function (expressed in neurons)Immune response (antigen implicated in autoimmune/paraneoplastic responses)Other (roles in testicular function, unclear additional functions)
04
Disease associations
Paraneoplastic disorders, especially paraneoplastic neurological syndromesCancer (particularly cancers associated with paraneoplastic syndromes)Neurological disorders linked to autoantibody generationOther (suspected role in mental retardation syndromes due to mutations in PNMA family members, although not specifically PNMA1)
05
Safety considerations
Immunogenicity: generation of anti-PNMA1 autoantibodies in patients may trigger harmful paraneoplastic neurological syndromesLimited understanding: physiological functions incompletely characterized, presenting uncertainty in targeting for therapy
06
Interacting drugs
Anti-PNMA1 antibodies (diagnostic)
07
Biomarkers
Anti-PNMA1 antibodies in patient serum serve as biomarkers for paraneoplastic neurological disorders and cancer diagnosis
Beyond the preview
Go deeper on PNMA family member 1 (PNMA1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PNMA family member 1 (PNMA1).